EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2),
(the "Company" or "EXM"), an emerging bio-science company
specializing in the production of unique cannabinoid formulations,
is pleased to announce the advancement of its R&D operations at
its Lisbon, Portugal, facility. The Company wishes to provide the
following updates with respect to ongoing R&D operations:
Earlier this year, EXM has applied for a P2020
Research Grant under the project name SkanABility for a
proof-of-concept study of the biological activity of cannabinoids
and terpenes in cosmeceutical applications. The project seeks to
demonstrate the commercial viability of cannabis compounds in
cosmetic and aromatherapy products, as well as develop sustainable,
functional packaging based on biodegradable cannabis materials
(fibres and waxes), which will allow for the extension of product
shelf-life and the preservation of formulations and properties.
SkanABility will develop formulations for different types of
cosmetics and aromatherapies (acne face cleansers,
anti-proliferative/regenerative, anti-inflammatory/hypoallergenic,
essential oils for aromatherapy, etc.) that EXM plans to sell to
industrial and pharmaceutical companies through a royalty-based
business model.
Recently, EXM submitted an application to the
Portuguese Government through the I&D COVID-19 initiative and
has begun investigating the virucidal efficacy of cannabis and
terpene molecules in combatting SARS-CoV-2, the virus that causes
COVID-19. Early indications suggest that the molecules may inhibit
the virus’ permanence on surfaces by attacking its cellular
structure. If proven effective, these molecules could become key
elements in commercial solutions used to combat the spread of the
virus.
EXM believes that these molecules will be
effective in reducing the spread of the virus and will be
applicable in the following key areas:
- The disinfection of surfaces and goods
- Hand and body disinfection
- The additional coating on social and surgical protective
masks
Currently available disinfectants often have
high alcohol contents of 60% or higher, which can be damaging to
fabrics, irritate skin, and can lead to illness if accidentally
ingested. Additionally, Hydrogen peroxide-based solutions are
flammable and corrosive to skin, eyes, and mucous membranes at high
concentrations (>10%) and may cause irritation. Disinfectants
containing natural cannabis and wild plant ingredients have
numerous potential advantages given that they are gentler on skin
and surfaces and more environmentally sustainable.
COVID-19 is an inflection point in our history
and has changed the way we view hygiene and cleanliness standards.
It created ultra-high demand for cleaning products across
industries, and consumers will seek out natural and effective
alternatives, such as the ones being explored by EXM, that are less
irritating to skin, less damaging to fabrics and surfaces, and the
most sustainable for the environment.
ON BEHALF OF THE BOARD OF DIRECTORS OF
EXMCEUTICALS INC.
Jonathan Summers, Chairman and Chief Executive
OfficerFor further information, contact: Investor Relations Email:
investors@exmceuticals.com
Media Enquiries:Email:
media@exmceuticals.com
FOR MORE UPDATES ON THE
COMPANY
Follow us on Twitter:
https://twitter.com/EXMceuticals Follow us on
LinkedIn:
https://www.linkedin.com/company/exmceuticalsinc/
ABOUT EXMCEUTICALS
EXM’s core activities are centred around the
strategic matching of natural bioactive ingredients extracted from
the cannabis plant with the needs of the nutraceutical,
cosmeceutical, and therapeutic industries. EXMceuticals Portugal,
obtained from INFARMED in November 2019, possesses unique
authorization for cannabis importation and research and development
at its specially equipped laboratory in Lisbon, Portugal. EXM's
team comprises highly qualified scientific and management
professionals covering all areas demanded by the cannabis industry
- organic and analytical chemistry, biology, biochemistry,
genetics, compliance, IP, partnerships, and legal and regulatory
issues.
EXM is in the final stages of detailed planning
for an industrial-scale pharmaceutical standard facility in
Portugal which will complement its existing R&D lab and pilot
refinery. An existing property has been secured in Setubal, south
of Lisbon, which requires retro-fitting to EU-GMP / API standards.
Once complete, the facility will contain extraction, purification,
and refining capabilities, as well as a Q&A laboratory. Once
built, we believe the Setubal facility will be the largest
cannabinoids and terpenes extraction, purification, and refining
facility in the European Union.
The refinery will be able to process cannabis
biomass, extracts, and distillates from Portugal, as well as from
international sources where the regulatory import requirements of
INFARMED have been met. EXM has multiple MOU’s in place which will
ensure the refinery can be operated to initial capacity from day 1
and then scaled further. This refinery, once licensed, will
distribute medical cannabis ingredients on a B2B basis, to produce
API’s and cannabis-based compounds in a reliable, consistent, and
standardized process. EXM targets and maintains the highest
certification standards to meet the needs of the pharmaceutical,
nutraceutical, and cosmetic industries worldwide.
CSE:
EXM| FSE:
A2PAW2
Neither the CSE nor the FSE has approved nor
disapproved of the contents of this news release. Neither the
CSE nor the FSE accepts responsibility for the adequacy or accuracy
of this release.
Certain information contained herein may
constitute "forward-looking information" under Canadian securities
legislation. Generally, forward-looking information can be
identified by the use of forward-looking terminology such as, "will
be", "expected", "proposes", "intends" or variations of such words
and phrases or statements that certain actions, events or results
"will" occur. Forward-looking statements regarding the Company's
business operations, the extraction of cannabis ingredients and the
exportation of the extracts, the results of testing at our
facilities established for the European market, future laws and
regulations governing the sale of our products in Europe and
elsewhere, and the potential to generate sales, and completion of a
Qualifying Financing, are subject to known and unknown risks,
uncertainties and other factors that may cause the actual results,
level of activity, performance or achievements of EXM to be
materially different from those expressed or implied by such
forward-looking statements or forward-looking information.
There can be no assurance that such statements will prove to be
accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward-looking
statements and forward-looking information. EXM will not update any
forward-looking statements or forward-looking information that is
incorporated by reference herein, except as required by applicable
securities laws.
EXMceuticals (CSE:EXM)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
EXMceuticals (CSE:EXM)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024